Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai InnoStar Bio-tech Co Net Margin %?
Shanghai InnoStar Bio-tech CoSHSE:688710 +7.65%35 Net Margin % is 5.81% as of Mar. 2026, which is 61% below its 10-year median of 14.78. GuruFocus rates SHSE:688710 with a GF Score™ of 35/100. The stock has 8 warning signs investors should review. Among 960 Drug Manufacturers companies, Shanghai InnoStar Bio-tech Co ranks worse than 70.21% on this metric.
The historical rank and industry rank for Shanghai InnoStar Bio-tech Co's Net Margin % or its related term are showing as below:
SHSE:688710'
s Net Margin % Range Over the Past 10 Years
Min: -3.76 Med: 14.78 Max: 18.72
Current: -2.93
SHSE:688710's Net Margin % is ranked worse than 70.21% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs SHSE:688710: -2.93
Shanghai InnoStar Bio-tech Co (SHSE:688710) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shanghai InnoStar Bio-tech Co Net Margin % Related Terms
Shanghai InnoStar Bio-tech Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688710 vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Shanghai InnoStar Bio-tech Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai InnoStar Bio-tech Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai InnoStar Bio-tech Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shanghai InnoStar Bio-tech Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a Net Margin % of 5.81% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. This is 61% below median its historical median of 14.78. According to the industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #674 out of 960 companies in the Drug Manufacturers industry, placing it in the top 70.2%.
Is Shanghai InnoStar Bio-tech Co's Net Margin % too high?
Shanghai InnoStar Bio-tech Co's current Net Margin % of 5.81% is 61% below median its 10-year median of 14.78. The Drug Manufacturers industry median Net Margin % is 5.64. Shanghai InnoStar Bio-tech Co's value of 5.81% is 3.1% above this industry median. Based on the distribution chart, Shanghai InnoStar Bio-tech Co ranks #674 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai InnoStar Bio-tech Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai InnoStar Bio-tech Co's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai InnoStar Bio-tech Co ranks #674 out of 960 companies for Net Margin %. This places Shanghai InnoStar Bio-tech Co in the lower half of its industry. The industry median Net Margin % is 5.64. Shanghai InnoStar Bio-tech Co's value of 5.81% is 3.1% above this benchmark. While the company's 10-year median is 14.78 vs. the industry median of 5.64, Shanghai InnoStar Bio-tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai InnoStar Bio-tech Co's current Net Margin % of 5.81% is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shanghai InnoStar Bio-tech Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai InnoStar Bio-tech Co's current Net Margin % is 5.81%, which is 61% below median its own 10-year median of 14.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai InnoStar Bio-tech Co stock overvalued right now?
Shanghai InnoStar Bio-tech Co (SHSE:688710) has a current Net Margin % of 5.81%. The current Net Margin % is 5.81%, which is 61% below median its 10-year median of 14.78 and 3.1% above the Drug Manufacturers industry median of 5.64. Shanghai InnoStar Bio-tech Co's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shanghai InnoStar Bio-tech Co (SHSE:688710), the current Net Margin % is 5.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai InnoStar Bio-tech Co Business Description
Shanghai InnoStar Bio-tech Co Ltd is a comprehensive research and development services (CRO) enterprise that specializes in providing biomedical non-clinical research services.
35GF Score
Get the complete analysis for SHSE:688710
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688710 has been successfully added to your 
